ArticleClinical endocrinology2018
Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.
Article in Clinical endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05362734 (Freeze All Strategy Versus Fresh Embryo Transfer After GnRH Analogue Trigger), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Freeze All Strategy Versus Fresh Embryo Transfer After GnRH Analogue Trigger
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- The letrozole use in reproductive medicine: Beyond aromatase inhibition - a comprehensive review.Turkish journal of obstetrics and gynecology · 2026Article
- Kisspeptins Regulating Fertility: Potential Future Therapeutic Approach in Infertility Treatment.Journal of clinical medicine · 2025Review
- Kisspeptin and neurokinin B: roles in reproductive health.Physiological reviews · 2025Review
- The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.Endocrine reviews · 2024Review
- Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction.Reproductive biology and endocrinology : RB&E · 2022Review
- Are anthropometric data a tool for determining the severity of OHSS? Yes, it could be!BMC women's health · 2022Observational
- Ovarian Hyperstimulation Syndrome (OHSS) requiring Intensive Care Unit (ICU) admission between 1996-2020 in England, Wales, and Northern Ireland.Frontiers in endocrinology · 2022Article
- Use of kisspeptin to trigger oocyte maturation duringFrontiers in endocrinology · 2022Review
- Prediction of severe ovarian hyperstimulation syndrome in women undergoingThe Journal of international medical research · 2020Article
- Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention.Upsala journal of medical sciences · 2020Review
- Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment.Frontiers in endocrinology · 2020Article
- FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation.Frontiers in endocrinology · 2019Article
- Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.Endocrine reviews · 2018Review
- Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.Clinical endocrinology · 2018Article
- Follicle Size on Day of Trigger Most Likely to Yield a Mature Oocyte.Frontiers in endocrinology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
Abstract
objectiveOvarian hyperstimulation syndrome (OHSS) is a serious iatrogenic condition, predominantly related to the hormone used to induce oocyte maturation during IVF treatment. Kisspeptin is a hypothalamic neuropeptide that has recently been demonstrated to safely trigger final oocyte maturation during IVF treatment even in women at high risk of OHSS. However, to date, the safety of kisspeptin has not been compared to current hormonal triggers of oocyte maturation.
designWe conducted a retrospective single-centre cohort study investigating symptoms and clinical parameters of early OHSS in women at high risk of OHSS (antral follicle count or total number of follicles on day of trigger ≥23) triggered with human chorionic gonadotrophin (hCG) (n = 40), GnRH agonist (GnRHa; n = 99) or kisspeptin (n = 122) at Hammersmith Hospital IVF unit, London, UK (2013-2016).
resultsClinical Parameters of OHSS: Median ovarian volume was larger following hCG (138 ml) than GnRHa (73 ml; P < .0001), and in turn kisspeptin (44 ml; P < .0001). Median ovarian volume remained enlarged 20-fold following hCG, 8-fold following GnRHa and 5-fold following kisspeptin compared to prestimulation ovarian volumes. Mean (±SD) ascitic volumes were lesser following GnRHa (9 ± 44 ml) and kisspeptin (5 ± 8 ml) than hCG (62 ± 84 ml; P < .0001). Symptoms of OHSS were most frequent following hCG and least frequent following kisspeptin. Diagnosis of OHSS: The odds ratio for OHSS diagnosis was 33.6 (CI 12.6-89.5) following hCG and 3.6 (CI 1.8-7.1) following GnRHa, when compared to kisspeptin.
conclusionTriggering oocyte maturation by inducing endogenous gonadotrophin release is preferable to the use of exogenous hCG in women at high risk of OHSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.